OXIS International, Inc. is engaged in the research, development and sale of products that counteract the harmful effects of “oxidative stress.”
Oxidative stress refers to the situations in which the body’s antioxidant and other defensive abilities to combat free radicals (a.k.a highly reactive species of oxygen and nitrogen) are overwhelmed and one’s normal healthy balance is either lost or severely compromised.Oxis products include therapeutic nutraceutical products, cosmeceutical products and proprietary formulations and clinical products that are developed internally and/or out-licensed to biotech and pharmaceutical companies as drug candidates.
They focus on naturally occurring protective substances since they are more likely to be both safe and efficacious. Their primary products incorporate and emphasize the multifaceted “super antioxidant” compound, L-Ergothioneine (“ERGO”), as a key component. They own several patents and pending applications related to ERGO that cover current and planned products relevant to our nutraceutical and cosmecuetical businesses. Oxis patents and patent applications address ERGO’s protective effects and activities and the ERGO manufacturing process. The head quarters of the Oxis International is present in the United states of America. Ergothioneine, a super anti oxidant , therapeutic compounds are supplied and an overview of the products are given by Oxis international which is considered to be the one of the best corporation.
